Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Current Opinion in Cell Biology|January 15, 2013
The Hippo superhighway: signaling crossroads converging on the Hippo/Yap pathway in stem cells and developmentEvan R Barry, Fernando D Camargo
Cells|October 23, 2021
Recent Therapeutic Approaches to Modulate the Hippo Pathway in Oncology and Regenerative MedicineEvan R Barry, Vladimir Simov, Iris Valtingojer, et al.
Expert Opinion on Therapeutic Targets|March 17, 2010
Targeting DOT1L action and interactions in leukemia: the role of DOT1L in transformation and developmentEvan R Barry, Gareth N Corry, Theodore P Rasmussen
Birth Defects Research. Part C, Embryo Today : Reviews|December 5, 2009
Epigenetic regulatory mechanisms during preimplantation developmentGareth N Corry, Borko Tanasijevic, Evan R Barry, et al.
Stem Cells (Dayton, Ohio)|June 23, 2009
ES cell cycle progression and differentiation require the action of the histone methyltransferase Dot1LEvan R Barry, Winfried Krueger, Caroline M Jakuba, et al.
Nature|November 27, 2012
Restriction of intestinal stem cell expansion and the regenerative response by YAPEvan R Barry, Teppei Morikawa, Brian L Butler, et al.
Oncotarget|July 30, 2016
Acquired savolitinib resistance in non-small cell lung cancer arises via multiple mechanisms that converge on MET-independent mTOR and MYC activationRyan E Henry, Evan R Barry, Lillian Castriotta, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 18, 2015
The MET Inhibitor AZD6094 (Savolitinib, HMPL-504) Induces Regression in Papillary Renal Cell Carcinoma Patient-Derived Xenograft ModelsAlwin G Schuller, Evan R Barry, Rhys D O Jones, et al.
Molecular Cancer Therapeutics|May 1, 2024
Activation of Hepatocyte Growth Factor/MET Signaling as a Mechanism of Acquired Resistance to a Novel YAP1/TEAD Small Molecule InhibitorCasey J Moure, Brandon Vara, Mangeng M Cheng, et al.
Journal of Medicinal Chemistry|April 30, 2026
Design of Novel Exatecan-Amide Linker-Payloads for the Development of Stable, Low-Aggregating, and Highly Efficacious Antibody-Drug ConjugatesRyan V Quiroz, Simon B Lang, Rebecca E Johnson, et al.
Pageof 2